TUALATIN-PORTLAND, OR, Nov. 16, 2021 (GLOBE NEWSWIRE) — iGrafx, a worldwide leader in digital business transformation and process management, announces that Abhijit Kakhandiki, business process management (BPM) and robotic process automation (RPA) industry veteran, will join iGrafx as a Board
Game-changing solutions built on the unique domain expertise of the technology and market leader in power grids which integrate with Hitachi’s Lumada platform Zurich, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) — Zurich, Switzerland, 16 November, 2021 – Further to its
DENVER, Nov. 16, 2021 (GLOBE NEWSWIRE) — Ensign-Bickford Industries, Inc. (EBI) today announced it has successfully closed on its acquisition of Cawood Scientific Limited (Cawood), headquartered in Bracknell, UK. Headquartered in Denver, CO, EBI is a 185-year-old privately held corporation
Featured Image for InDevR, Inc. BOULDER, Colo., Nov. 16, 2021 (GLOBE NEWSWIRE) — InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its new
Launching November 2021, Dingles by The Secret Order of Lumiiis is a collection of NFTs (non-fungible tokens) on the Solana blockchain that pays daily rewards in the form of LumiiiTokens, the official governance token of the Lumiii ecosystem. TORONTO, Nov.
CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) — Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd.
SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors.
